Development of effective treatments for alcohol use disorder (AUD) represents an important public health goal. This review provides a summary of completed preclinical and clinical studies testing pharmacotherapies for the treatment of AUD. We discuss opportunities for improving the translation from preclinical findings to clinical trial outcomes, focusing on the validity and predictive value of animal and human laboratory models of AUD. Specifically, while preclinical studies of medications development have offered important insights into the neurobiology of the disorder and alcohol's molecular targets, limitations include the lack of standardized methods and streamlined processes whereby animal studies can readily inform human studies. Behavioral pharmacology studies provide a less expensive and valuable opportunity to assess the feasibility of a pharmacotherapy prior to initiating larger scale clinical trials by providing insights into the mechanism of the drug, which can then inform recruitment, analyses, and assessments. Summary tables are provided to illustrate the wide range of preclinical, human laboratory, and clinical studies of medications development for alcoholism. Taken together, this review highlights the challenges associated with animal paradigms, human laboratory studies, and clinical trials with the overarching goal of advancing treatment development and highlighting opportunities to bridge the gap between preclinical and clinical research.
INTRODUCTION
Alcohol use disorder (AUD) has a major public health impact in the USA affecting nearly 18 million people and causing over 100,000 deaths annually (Harwood, 2000; Grant et al., 2004; Bouchery et al., 2011) . Worldwide, alcohol abuse and misuse is the third leading risk factor for premature death and disabilities and is responsible for 4% of all deaths (World Health Organization, 2011) . Although treatments for AUD have improved in the past decades (Miller et al., 2011) , there is still a great need to develop more effective interventions. Pharmacotherapies for AUD are used less often than psychosocial interventions (Fuller and Hiller-Sturmhofel, 1999 ), yet without a pharmacological adjunct to psychosocial therapy nearly three quarters of patients resume drinking within 1 year (Johnson, 2008) . The limited use of pharmacotherapy for AUD is due, in part, to the relative lack of pharmacological options to successfully treat this disorder (Edlund et al., 2012) . As such, development of effective treatments for AUD represents an important public health goal (Heilig and Egli, 2006; Johnson et al., 2007; Steensland et al., 2007; Johnson, 2010; Bouchery et al., 2011) . Litten et al. (2012) have argued that there are three overarching aims for ensuring the successful development of novel therapeutics for AUD: (1) improve the drug development process, (2) identify more effective therapeutics and/or use personalized medicine, and (3) enable the use of these novel medications in clinical practice. In order to achieve these goals, Litten et al. emphasize the importance of bridging the gap between preclinical and clinical research. In this paper, we will provide a perspective on medications development and a review of the pharmacotherapies for AUD that have been tested using animal paradigms, human laboratory paradigms, and clinical trials focusing on the validity and predictive value of animal and human laboratory models of AUD. To do so, we will first discuss the neural targets of alcohol in relation to medications development including both the traditional targets, such as ligand-gated ion channels and the endogenous opioid system, and novel targets such as ghrelin and neuropeptide Y (NPY). We will then delve into a review of the literature focused on identifying the challenges associated with animal paradigms, human laboratory studies, and clinical trials with the overarching goal of advancing treatment development and highlighting opportunities to bridge the gap between preclinical and clinical research.
Neural targets of alcohol
One of the major obstacles for developing effective drugs for the treatment of AUD is that alcohol does not have a single molecular target but instead acts on a variety of different neurotransmitter receptors, ion channels, transporters, and pathways in the central nervous system (CNS) to exert its behavioral effects (for a review, see Gilpin and Koob (2008) , Koob and Volkow (2010) , Soderpalm and Ericson (2013) , Spanagel (2009) , and Weiss and Porrino (2002) ). Although not the focus of this review, we will briefly introduce some of the more prominent targets as they relate to medications development for AUD.
A long-standing belief is that alcohol interacts with the mesolimbic dopamine (DA) pathway to produce its behavioral effects (for a review, see Gonzales et al. (2004) and Pierce and Kumaresan (2006) ). Specifically, DA release in the nucleus accumbens (NAc) is thought to be central in the motivation and positive reinforcement associated with acute alcohol administration. Alcohol causes an increase in synaptic DA concentration in the NAc similar to other drugs of abuse (Di Chiara and Imperato, 1988; Gessa et al., 1985) . Importantly, many of the targets described in the succeeding discussions do indirectly affect DA neurotransmission.
Ligand-gated ion channels are widely held to play an important role in ethanol-induced behaviors (for a review, see Dopico and Lovinger (2009) , Harris et al. (1995) , and Spanagel (2009) ). Research in this area has focused on investigating the effects of ethanol on two large superfamilies of ligand-gated ion channels. The first is the Cys-loop superfamily including nicotinic acetylcholine receptors (nAChRs), 5-hydroxytryptamine type 3 receptors (5-HT 3 Rs), gamma-aminobutyric acid type A receptors (GABAARs), and glycine receptors. Varenicline, an FDA-approved smoking cessation aid, is a full and partial agonist at several nAChR subtypes and has been shown to attenuate the reinforcing effects associated with alcohol in both mice (Blomqvist et al., 1996; Steensland et al., 2007) and humans (Fucito et al., 2011; Mitchell et al., 2012c; Litten et al., 2013) , while others suggest it might be effective in reducing alcohol consumption by exacerbating the negative effects of alcohol (Childs et al., 2012; Kamens et al., 2010) . Ondansetron, a 5-HT 3 R antagonist, has been shown to decrease alcohol intake in preclinical studies (Tomkins et al., 1995) and decrease alcohol intake in early onset alcoholics in several clinical trials (Johnson et al., 2000; Kranzler et al., 2003) possibly through decreasing alcohol craving and diminishing the pleasurable effects associated with alcohol (for a review, see Ye et al. (2001) ). The second superfamily of ligand-gated ion channels that are targets for alcohol action is the glutamate superfamily with members including α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), kainate receptors, and N-methyl-D-aspartate receptors (NMDARs) (for a review, see Dodd et al. (2000) , Moykkynen and Korpi (2012) , and Tsai and Coyle (1998) ). Acamprosate, one of the three FDA-approved medications for AUD, is an NMDAR antagonist and has been shown to prevent relapse in alcohol-dependent (AD) individuals acting as an anticraving medication (for a review, see Littleton (1995) and Witkiewitz et al. (2012) ). Additionally, memantine, another NMDAR antagonist, currently used in the treatment of moderate to severe dementia, has shown great promise in preclinical studies (Piasecki et al., 1998; Sabino et al., 2013) , yet the sole clinical trial conducted on memantine for AUD yielded negative results (Evans et al., 2007) .
P2X receptors (P2XRs) constitute a third superfamily of ligand-gated ion channels that are becoming a focus of investigation in neuroscience and alcohol studies (for a review, see Asatryan et al. (2011) ). Preclinical studies suggest that ivermectin, a selective, positive allosteric modulator of P2X4R, is able to decrease alcohol selfadministration in wild-type mice using multiple models of alcohol intake but to a lesser extent in P2X4R knockout mice (Yardley et al., 2012; Wyatt et al., 2014) .
Another well-known target of alcohol in the CNS is the endogenous opioid system (for a review, see Gianoulakis et al. (1996) and Herz (1997) ). There are three known opioid receptor subtypes: μ, δ, and κ. In addition to endogenous opioid peptides: β-endorphins, enkephalins, and dynorphins, exogenous ligands, such as morphine, also act on the opioid receptors. Naltrexone, one of the three drugs approved by the FDA for the treatment of AUD, blocks opioid receptors and is believed to decrease the reinforcing effects of alcohol (for a review, see Johnson (2008) ). Nalmefene, another opioid receptor antagonist with a mechanism of action similar to naltrexone, is currently being developed as a medication for AUD in the USA but has already received European marketing authorization (for a review, see Paille and Martini (2014) ).
Novel targets are being actively explored. One such novel target is the ghrelin receptor. Ghrelin is known to stimulate food consumption through indirect interaction with the hypothalamus; however, there is evidence that it also plays an important role in alcohol consumption (for a review, see Vadnie et al. (2014) ). Additional studies suggest ghrelin might also play a role in alcohol craving (Leggio et al., 2012; Leggio et al., 2014) , reward , and withdrawal and relapse (Suchankova et al., 2013) , but the exact role of ghrelin in mediating the behavioral effects of alcohol remains unknown.
The endocannabinoid (EC) system and its involvement in alcohol dependence have received much attention since the identification of the cannabinoid 1 receptor (CB1) (for a review, see Ciccocioppo et al. (2009) , Hungund and Yaragudri (2009), Pacher et al. (2006) , and Pava and Woodward (2012) ). Due to the comorbidity of cannabis use and AUD, it has been suggested that cannabis and alcohol may act on similar targets in the CNS. Rimonabant, a cannabinoid receptor 1 blocker, appears to be effective in reducing consumption in multiple preclinical models of alcohol self-administration (Arnone et al., 1997; Gessa et al., 2004; Cippitelli et al., 2005) , yet clinical studies conducted thus far do not support the use of rimonabant for treatment of AUD (Soyka et al., 2008; George et al., 2010) .
There are a number of stress-related neuropeptides that have been implicated as important targets for alcohol such as NPY, corticotropin-releasing factor, and nociceptin/orphanin FQ (N/OFQ) signaling (for a review, see Ciccocioppo et al. (2009) and Heilig and Egli (2006) ). NPY is believed to play a role in alcohol intake, dependence, and withdrawal via interruption of NPY signaling by alcohol (for a review, see Thiele and Badia-Elder (2003) , Thorsell (2007) , and Vadnie et al. (2014) ). NPY is an endogenous ligand shown to have anxiolytic and anti-depressant properties that might contribute to its ability to attenuate alcohol consumption. Corticotropinreleasing factor is another stress-related neuropeptide and appears to be involved in excessive alcohol consumption in post-dependent animals, stress-induced reinstatement of alcohol seeking, and anxiety associated with alcohol withdrawal (for a review, see Heilig and Koob (2007) ). Lastly, N/OFQ, an endogenous ligand for the nociception receptor (NOP), has been shown to block drug-induced increases in extracellular DA in the NAc (for a review, see Heilig and Egli (2006) ).
Neurotrophic factor signaling represents an important target for medications development for AUD (for a review, see Janak et al. (2006) and Russo et al. (2009)) . Multiple neurotrophins such as brain-derived neurotrophic factor, neurotrophin 3, and neurotrophin 4 have been implicated in drug addiction (for a review, see Janak et al. (2006) ). In more recent years, the neuroimmune signaling pathway has garnered attention as a probable target for alcohol action, specifically in regard to its role in intoxication, negative affect, and craving (for a review, see Coller and Hutchison (2012) and Mayfield et al. (2013) ). Both human and animal studies provide support for the role of alcohol-induced neuroimmune signaling (for a review, see Coller and Hutchison (2012) ). Pioglitazone, a peroxisome proliferator-activated receptor agonist, has generated positive results in preclinical studies, but results from clinical studies have not yet been published (for a review, see Robinson et al. (2014) ).
Despite the long list of implicated targets of alcohol action, demonstrations in humans are still lacking, and the specific contributions of these targets are only recently beginning to be explored (Mitchell et al., 2012b) . Molecular targets such as the Cys-loop and glutamate superfamily of ligand-gated ion channels and the mesolimbic dopamine pathway are widely accepted as being important in alcohol's action (Johnson, 2008) . Others, such as P2X4Rs, ghrelin receptors (Vadnie et al., 2014) , the EC system (Johnson, 2008) , and neuroimmune signaling (for a review, see Coller and Hutchison (2012) and Mayfield et al. (2013) ) have been clinically investigated as possible targets of alcohol action more recently. These novel targets have become the focus of medications development for AUD. Table 1 details medications that have previously undergone or are currently undergoing testing that were identified from clinicaltrials.gov. The primary indication and mechanism of action is listed for each. In the following sections, using the medications included in Table 1 , we will discuss three different stages of medications development for AUD: preclinical, human laboratory, and clinical research. For each stage, we will briefly discuss commonly used paradigms, limitations associated with these models, and recommendations to increase the successful translation of a drug from preclinical to clinical research. Not all medications in Table 1 have been tested in each stage of drug development, and as a result, these medications are excluded from subsequent tables as no results are yet published.
Animal paradigms
After considering the molecular targets of alcohol itself, we turn our attention to medications development for AUD at the preclinical level. Table 2 provides a detailed summary of preclinical studies using multiple animal paradigms thought to model different facets of alcoholism with the ultimate goal of testing medications that can be advanced from preclinical to clinical testing. To that end, one of the most common and important phenotypes studied using animal models is alcohol intake. There are numerous paradigms used to model social drinking, excessive alcohol consumption, and operant self-administration of alcohol in animals. The two-bottle choice paradigm is a frequently used model of social drinking because animals do not generally achieve clinically relevant blood alcohol concentrations (BACs; for a review, see Crabbe et al. (2011) and Tabakoff and Hoffman (2000) ). In the twobottle choice paradigm, animals have continuous access to one bottle of alcohol and one bottle of water and are able to choose freely between the two. Chronic intermittent access, scheduled high alcohol consumption, drinking in the dark, and chronic intermittent vapor exposure are some of the more commonly employed animal models of excessive alcohol consumption (for a review, see Becker and Ron (2014) and Crabbe et al. (2011) ). There are numerous variations to each paradigm; however, in each case, the animals reach intoxicating BACs. Operant self-administration is unique in that it allows for evaluation of the animal's motivation to consume alcohol (for a review, see Cunningham et al. (2000) and Tabakoff and Hoffman (2000) ). In this paradigm, animals are trained to press a lever to receive alcohol; however, the frequency of access to alcohol, amount of alcohol available, and number of lever presses required to gain access to alcohol can be adapted.
Although preclinical research represents a crucial step in the drug development process, several factors must be considered when using animals to model human behavior. Results from preclinical studies can vary depending upon the strain and species used. For example, the study conducted by Breslin and colleagues (2010) found that treatment with topiramate decreased alcohol consumption in alcohol-preferring (P) rats but had no effect on alcohol consumption in Wistar rats (Breslin et al., 2010) . Furthermore, studies reported differences in response to medication between AD and non-AD rats (Roberto et al., 2008) and high-preference and Decreased alcohol intake (Froehlich et al., 1990) Decreased alcohol intake in h/mOPRM1-118GG mice only (no effect in 118AA mice) (Bilbao et al., 2015) Operant self-administration Decreased operant self-administration of alcohol (Bilbao et al., 2015; Gonzales and Weiss, 1998; Le et al., 1999; Steensland et al., 2007; Tanchuck et al., 2011; Walker and Koob, 2008 ) Scheduled high alcohol consumption Decreased alcohol intake (Tanchuck et al., 2011) (Kiianmaa et al., 1983) Alcohol discrimination Failed to alter discrimination of alcohol (Middaugh et al., 1999 ) Alcohol-induced mesolimbic dopamine release Prevented alcohol-induced mesolimbic dopamine release (Gonzales and Weiss, 1998) Alcohol deprivation effect Diminished alcohol deprivation effect (naltrexone + acamprosate also reduced ADE) (Heyser et al., 2003) Alcohol-induced reinstatement of alcohol-seeking behavior Diminished alcohol-induced reinstatement (Le et al., 1999) Stress-induced reinstatement of alcohol-seeking behavior
No effect (Le et al., 1999) Intravenous self-administration Dose dependently decrease self-administration in rhesus monkeys (Altshuler et al., 1980) Acamprosate 24-h access two-bottle choice voluntary intake
Decreased alcohol intake in high-preference rats; No effect on low-preference rats (Oka et al., 2013) Limited access two-bottle choice voluntary intake Decreased alcohol intake (Olive et al., 2002) Alcohol-induced mesolimbic dopamine release Suppressed alcohol-induced mesolimbic dopamine release (Olive et al., 2002) Drinking in the dark Decreased alcohol intake (Gupta et al., 2008) 
Alcohol discrimination
Failed to alter discrimination of alcohol (Spanagel et al., 1996c) Operant self-administration No effect in alcohol preferring rats (Spanagel et al., 2014 ) Alcohol deprivation effect Diminished alcohol deprivation effect (Heyser et al., 1998; Oka et al., 2013; Spanagel et al., 1996a) No effect (Spanagel et al., 2014) 
Alcohol withdrawal
Reduced some withdrawal signs (Spanagel et al., 1996b ) Cue-induced reinstatement of alcohol-seeking behavior Reduced ethanol-paired cue effects (Bachteler et al., 2005) No effect (Spanagel et al., 2014 ) Nalmefene Operant self-administration Decreased operant self-administration of alcohol (Bilbao et al., 2015; Nealey et al., 2011; Walker and Koob, 2008 ) Fluid deprivation + limited access two-bottle choice voluntary intake Decreased alcohol intake (Hubbell et al., 1991) (Continues) (Gabriel and Cunningham, 2005) Decreased alcohol intake at 2-h time point but not at 21-h time point in C57BL/6J (Ngyuen et al., 2007) Decreased alcohol intake in P rats; No effect in Wistar rats (Breslin et al., 2010) Three Decreased alcohol intake (Stopponi et al., 2012) Operant self-administration Decreased operant self-administration of alcohol; No effect on operant responding for food (Stopponi et al., 2012) Stress-induced reinstatement of alcohol-seeking behavior Inhibited reinstatement (Stopponi et al., 2012) Cue-induced reinstatement of alcohols-seeking behavior Diminished cue-induced reinstatement (Stopponi et al., 2012) Baclofen Alcohol withdrawal Decrease in total score of intensity of ethanol withdrawal in dependent rats (Colombo et al., 2000) Reduced withdrawal signs in ethanol-withdrawn rats (Knapp et al., 2007b) 24-h access two-bottle choice voluntary intake
Decreased alcohol intake (Colombo et al., 2000) Scheduled high alcohol consumption Decreased alcohol intake (Tanchuck et al., 2011) Operant self-administration No effect (Tanchuck et al., 2011 ) Decreased operant self-administration of alcohol in dependent and non-dependent rats (Walker and Koob, 2007) Decreased alcohol-reinforced responding (Besheer et al., 2004) (Continues) Decreased alcohol intake (Stopponi et al., 2011) Operant self-administration Decreased operant self-administration of alcohol (Stopponi et al., 2011) Stress-induced reinstatement of alcohol-seeking behavior Diminished stress-induced reinstatement (Stopponi et al., 2011) Cue-induced reinstatement of alcohol-seeking behavior
No effect (Stopponi et al., 2011) Alcohol withdrawal Reduced withdrawal signs (Stopponi et al., 2011) Mecamylamine 24-h access two-bottle choice voluntary intake Decreased alcohol intake (Farook et al., 2009) Alcohol-induced dopamine release Prevented alcohol-induced dopamine release (Blomqvist et al., 1997 Ericson et al., 1998 Larsson et al., 2002) (Continues)
low-preference rats (Oka et al., 2013) . A similar phenomenon is observed in clinical studies, whereby treatment response appears to be dependent on treatment population. Nevertheless, a deeper understanding of why a drug is effective in one strain or one species and not another is often elusive. Delving into these differences may ultimately inform precision medicine efforts. In addition to strain, alcohol intake can also fluctuate depending on the concentration of the alcohol solution and the addition of a sweetener (Yoneyama et al., 2008) . Another important issue to consider is that drugs are rarely compared against each other at a preclinical level but rather are tested against a placebo. Using the field standard, such as naltrexone, in models where the drug Lallemand et al., 2001) has already shown efficacy, as a comparison may help to identify the animal paradigms that are predictive of human behavior through reverse translation. Perhaps equally important, reverse translation could prove informative for promising medications that do not show clinical efficacy as a means of identifying responders via animal and human laboratory studies. Unfortunately, reverse translation is uncommon as many compounds that progress to advanced stages of clinical drug development rarely endure additional testing at the preclinical level to validate the animal paradigms. Furthermore, unlike in human testing, animals are not susceptible to the 'placebo effect' (van der Worp et al., 2010), which likely leads to an overestimation of the medication effects in animal models. In other words, the signal-to-noise ratio is clearly higher in animal studies, yet the 'signal' often fades and is no longer detectable or clinically relevant when tested in clinical samples. It is also important to consider that FDA-approved drugs that are being investigated for other indications often do not follow a linear progression from preclinical to clinical stages of drug development. For example, dutasteride, approved for the treatment of benign prostatic hyperplasia, has been tested in human laboratory studies for the treatment of AUD (Table 3) , but no animal studies have been published for this indication thus far (Table 2) . In other cases, such as nalmefene and varenicline, there are relatively fewer reported preclinical studies (Table 2) as compared with clinical studies (Table 3 and 4) .
Although preclinical development represents an important part of the drug development pathway, there are many factors that limit the usefulness of these models in their current format. One such obstacle may be publications bias. For example, one study analyzed over 4600 published papers across disciplines in 2007 and found that 85.9% of papers reported a positive result (Fanelli, 2012) . This strong bias towards positive publications makes it extremely difficult to draw conclusions between the predictive validity of animal data to clinical outcomes. Furthermore, despite the misconception that negative results are not as valuable as positive results, reporting of negative results can allow for refinement of theories or methods, encourage discussion within the field, improve quality control, and ultimately help to advance science by filling gaps in knowledge (Lehrer et al., 2007; Matosin et al., 2014) . Data repositories may be helpful in increasing access to preclinical findings and mitigating the issue of publication bias.
In summary, preclinical studies of medications development for AUD have offered important insights into the neurobiology of the disorder and alcohol's molecular targets. Current limitations of this approach include the lack of standardized methods and streamlined processes whereby animal studies can readily inform human studies, which in turn would start at the point of safety and initial efficacy (described in the succeeding discussions).
Human laboratory paradigms
Human laboratory studies offer unique opportunities to gain insight into the safety, efficacy and most importantly, the mechanism of action of the drug being tested, serving as a less expensive alternative compared with full-scale clinical trials. Table 3 summarizes the results of human laboratory studies investigating the mechanism by which drugs being developed for the treatment of AUD exert their effect. As exemplified in Table 3 , there are numerous laboratory paradigms used to model facets of AUD (Ray et al., 2010) . Commonly used paradigms include alcohol self-administration, experimenter administered alcohol (i.e., alcohol challenge), alcohol cue-reactivity, and stress induction. For example, in one iteration of the alcohol self-administration paradigm, participants complete two 1-h self-administration (SA) periods having the option of consuming up to four alcoholic drinks (0.015 g/dl each) or receiving a monetary compensation of $3 per beverage not consumed . Typically, the total number of drinks consumed during the SA sessions is considered the primary outcome variable and rate of drinking (i.e., time to first drink and inter-drink interval) is often used as a secondary outcome. Regarding the ethics of alcohol administration to clinical samples, it is important to note that many studies have assessed the effect of laboratory self-administration of alcohol on future alcohol use and found that alcohol use does not increase in subjects following participation in an alcohol administration study (Pratt and Davidson, 2005; Sommer et al., 2015) . Importantly, the National Advisory Council on Alcohol Abuse and Alcoholism's recommended council guidelines on ethyl alcohol administration in human experimentation encourages experiments involving alcohol administration to be conducted in non-treatment-seeking subjects (Enoch et al., 2009 ). Yet, because of the distinct differences between nontreatment-seeking and treatment-seeking populations and given the lack of successful medications to treat this disorder, the benefits to society oftentimes outweigh the risks to the individual. Additional human laboratory paradigms include stress and cue-reactivity. The cue-reactivity paradigm measures alcohol craving (Bohn et al., 1995; MacKillop, 2006) . In this paradigm, participants are asked to hold and smell a glass of water for 3 min to control for the effects of simple exposure to any potable liquid. Next, participants hold and smell a glass of their preferred alcoholic beverage for three 3-min trials (Monti et al., 1987; Monti et al., 2001) . After every 3 min of exposure, craving for alcohol is assessed. Given the number of studies that suggest an association between stress and alcohol use, stress induction in the laboratory has been used to understand the relationship between stress-induced and cue-induced craving in relation to alcohol use (Plebani et al., 2012) . Two paradigms are often used to induce stress in the laboratory: (1) the Trier Social Stress Test [TSST; (Kirschbaum et al., 1993) ] and 2) guided imagery exposure to a stressful event (Sinha et al., 1999) . In addition to behavioral assessments, brain imaging techniques can provide additional insight into the mechanism of the pharmacotherapies being tested. Although beyond the scope of this review, brain imaging studies have become increasingly popular in clinical and therapeutic developments in addictive disorders (Fowler et al., 2007) , with a particular focus on the neural bases of cue-reactivity (Jasinska et al., 2014) . A review by Borsook et al. (2011) highlights the importance of brain imaging in bridging preclinical and clinical CNS drug discovery. Specifically, they emphasize that this technique may be able to help better identify pharmacodynamic markers, improve paradigms to predict efficacy, evaluate safety, elucidate dose-response relationships, and more accurately define symptom response. As noted in a recent review by our group, neural markers, in particular those during cue reactivity, appear to be promising predictors of relapse in clinical contexts (Courtney et al., 2015) . Taken together, these paradigms and techniques used in behavioral pharmacology studies provide insight into the mechanism of action of the drug; however, certain precautions, such as sample size and consideration of inclusion and exclusion criteria due to known variations in response associated with certain clinical characteristics, need to be taken to ensure the conclusions reached are valid.
As discussed for animal studies, different populations respond differently to each drug; therefore, Table 3 is organized according to the lab paradigm and sample tested. In the study by Drobes et al. (2003) , naltrexone decreased alcohol self-administration in a naturalistic setting in non-treatment-seeking AD individuals but had no effect on social drinkers in the same study, non-treatment-seeking AD individuals (O'Malley et al., 2002; Anton et al., 2004a) or heavy beer drinkers (Davidson et al., 1999) suggesting that the results of each study should be interpreted carefully and the population tested must be taken into consideration. Interestingly, human laboratory studies are more often conducted in non-treatment-seeking AD individuals, whereas clinical trials employ treatment-seeking AD individuals, which likely accounts for the at least part of the discrepancy between results from human laboratory studies and clinical trials. It remains unclear what variables differentiate treatment seekers from non-treatment seekers for alcoholism, whether it be severity of the disorder or the act of treatment seeking itself. Importantly, epidemiological week from single-blind placebo phase to treatment phase (Mason et al., 1994) Both doses compared with placebo: Decreased change in number of drinks per drinking day from single-blind placebo phase (Mason et al., 1994) (Continues) No effect on % HDD or % subjects with no HDD Gabapentin 3 days 12 weeks/ 2 X 150 mg t.i.d.; 2 X 300 mg t.i.d.
Dose dependently increased rates of complete abstinence and no heavy drinking (Mason et al., 2014) Patients with moderate-severe AWS; 0 days 2 days/ 400 mg q.i.d. (data on safety and tolerability continued to be measured until day 7)
No effect on amount of CLO required in the first 24 hours (no psychosocial component specified) (Bonnet et al., 2003) Pregabalin 5 Increased % abstinent and cumulative abstinent duration (Addolorato et al., 2007) 3 days 12 weeks/30 mg per day (dosing schedule not specified)
No effect on % HDD (Garbutt et al., 2010) 3 days 12 weeks/10 mg t.i.d. data suggest that there is an average lag of 8 years between AUD onset and treatment seeking (Hasin et al., 2007) . Ongoing studies in our laboratory suggest that treatment seekers are older and have a more severe AD presentation, as compared with non-treatment seekers. Additional attention to discrepancies in sample characteristics between human laboratory and clinical trials is likely to promote greater consilience across approaches. In addition to the variance regarding drinking status and treatment-seeking efforts, sample size is another significant factor contributing to the lack of predictability between human laboratory studies and clinical trials. Human laboratory studies tend to have a much smaller sample size compared with clinical trials and, therefore, may affect the reliability of the estimates. The average samples size for the human laboratory studies included in Table 3 is 47 ± 48 participants, whereas the average sample size for the clinical trials listed in Table 4 is 207 ± 235 participants. Unlike the p-value, effect size is independent of sample size and indicates the magnitude of the effect (Sullivan and Feinn, 2012) . Therefore, both effect size and p-value should be considered when interpreting and comparing results from human laboratory studies and clinical trials.
Similar to the preclinical models, human laboratory studies could be strengthened if the drugs of interest were tested against a field standard pharmacotherapy instead of, or in addition to, a placebo treatment (Rothman and Michels, 1994) . Arguments can be made that placebos offer a more suitable reference for determining efficacy, provide a more straightforward comparison, and increase the likelihood of achieving statistical significance; however, the use of active medication as a comparison can be beneficial to establish whether the new treatment is superior to the currently available/approved treatment. It is important to acknowledge that comparison to a placebo may be important in earlier stages of development to establish initial efficacy. However, later in the development, it might be more informative to include both a placebo arm and a gold standard arm although this introduces additional challenges as it requires a larger sample. Comparing multiple doses of the drug could also provide a strategic method for conducting dose-finding studies prior to proceeding to relatively expensive clinical trials.
Another important issue to consider is the monetary compensation of research subjects, which provides an incentive for non-treatment-seeking subjects and can strongly influence participation in the research study (Grady, 2005) . As these subjects are not seeking medical benefit from the treatment, their primary motivation to participate in the research study is the monetary compensation; investigators should guard against the compensation becoming coercive or an excessive inducement. Further, there are concerns that the motivation for monetary compensation itself could lead to a general disinterest in the study and low level of concern about data accuracy. A recent commentary by Resnik and McCann (2015) highlights this complex issue. The authors cite a recent study reporting that a quarter of respondents admitted to exaggerating their symptoms and 14% pretended to have a health problem to qualify for a study. While these concerns are often mitigated by an effective consent process and by forming a strong alliance with research participants as they are helping others with similar conditions through their participation in research studies, Resnik and McCann suggest that additional strategies can be used to address this concern including the use of laboratory tests to confirm self-reported information, the use of reinforcements to promote truthfulness, and increased utilization of available clinical trial registries.
In sum, considering clinical costs associated with drug development are estimated to be more than $500 million, it is crucial to find novel ways to improve the translational predictability between relatively less expensive human laboratory studies and clinical trials (Paul et al., 2010) . Specifically, phase I studies can provide a less expensive and extremely valuable opportunity to assess the feasibility of an approach prior to initiating larger scale clinical trials such as identifying a specific population more likely to respond to the medication and issues concerning retention, analyses, assessments, and so on (Leon et al., 2011) . These studies can then be used to establish standardized procedures in regard to environment, treatment goals, and drinking severity of the population as well as sample size. Limitations notwithstanding, before the FDA will approve a drug, clinical trials must be conducted.
Clinical trials
A relatively small percentage of drugs successfully make the transition from preclinical studies to clinical development, and even fewer make it all the way through phase III clinical trials (Paul et al., 2010) . Table 4 summarizes the results from clinical trials on drugs being developed as treatments for AUD. As evident in Table 4 , clinical trials usually employ multiple primary efficacy outcomes such as time to first heavy drinking day (HDD), time to first lapse, days abstinent, maintenance of abstinence, drinks per drinking day, and percent drinking days. In addition to the outcomes measured, duration of trial, time abstinent prior to the clinical trial, and dosing regimen are also variable across trials of different drugs and different trials of the same drug, as illustrated in Table 4 . Once again, the lack of standardized methods among clinical trials and between human laboratory studies and clinical trials hinders the translation from human laboratory findings to clinical outcomes. First, although there tends to be less heterogeneity regarding drinking status and treatment-seeking status in clinical trial participants, there are marked differences in AD phenotype and treatment goals that have been shown to alter the effect of medication (Bujarski et al., 2013; DeMartini et al., 2014) . For instance, analyses of the COMBINE Study found that a goal of complete abstinence was associated with an increase in percent days abstinent, days to relapse to heavy drinking, and global clinical outcome compared with a goal of conditional abstinence or controlled drinking (Bujarski et al., 2013) . Therefore, it is important to acknowledge the known, clinically significant differences between human laboratory and clinical trial participants when drawing associations between human laboratory results and clinical trial outcomes. Similarly, it is important to recognize there are differences not only between but also within each population as well and these should be considered when interpreting data.
In clinical trials, the FDA requires investigators to commit to an a priori hypothesis as stated in the Guidance for Industry Patient-reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, making the selection of an appropriate endpoint imperative (2009). This guidance requires investigators to thoroughly consider the aims of the clinical trial prior to execution by having them declare the hypothesis and primary outcomes ahead of time allowing investigators to test for statistical significance (Furberg and Furberg, 2007) . The analyses are focused specifically on the predetermined outcome(s) and represent an important safeguard to eliminate coincidental findings. Therefore, selection of an appropriate hypothesis and outcome measures becomes extremely vital for the proper evaluation of a drug in clinical trials.
The FDA recommends that percent subjects with no heavy drinking days (PSNHDDs) be the primary endpoint measure for phase III clinical trials evaluating pharmacotherapy for AUD (FDA, 2006) . Further examination of the utility and validity of this particular outcome measure was pursued by Falk et al. (2010) who concluded that not only was this endpoint clinically relevant and as sensitive as other endpoints such as percent subjects abstinent, percent days abstinent, drinks per day, drinks per drinking day or drinks per drinking week but also that a grace period should be used where appropriate. For example, studies involving medications that require titration to reach the target dose should allow a grace period to ensure subjects are receiving the full effect of the medication prior to evaluation. Additionally, studies might include a grace period to confirm that participation in the clinical trial itself, is not the only factor affecting changes in drinking habits. Allowing the novelty of participating in a clinical trial to diminish prior to evaluation could be especially important in preventing false negatives that can arise with the use of a placebo.
Importantly, as many clinical trials compare the treatment under investigation with placebo, there are ethical issues that arise from administering placebo to a treatment-seeking population of individuals with AUD when there is a known, effective treatment. Furthermore, given that Weiss et al. (2008) found that administration of placebo medication in the COMBINE study leads to a significant 'placebo effect', it is important to consider that the use of a placebo could potentially lead to false negatives. A possible avenue to addressing the placebo effect is to provide less robust behavioral interventions within the treatment protocol and to provide longer duration of trial and follow-up, which could unmask 'real' medication versus placebo differences emerging over time.
In brief, clinical development (phase I-III studies) represents the most expensive part of drug development, making up just over 60% of the total cost, highlighting the need for a streamlined process (Paul et al., 2010) and utilization of alternative methods to reduce costs. One possible solution for alleviating the financial burden associated with clinical trials is through the use of interim analyses as it allows for the investigator to halt the study when there is enough data available to reach a conclusion (Todd et al., 2001 ). Not only is this beneficial in terms of financial obligations but it also carries significant ethical implications.
Moving from the human laboratory to the clinic
The potential translational value of animal, human laboratory and clinical studies can be better achieved through refinements of the drug development process to ensure the successful development of novel therapeutics for AUD . To more fully appreciate the predictive value of preclinical and human laboratory results to clinical outcomes, we have classified each study, including drugs with at least three or more reported clinical trials, as either positive or negative ( Fig. 1 ; Supporting Information Table 1 ). For the purposes of this summary figure, if the human laboratory study or clinical trial showed a statistically significant positive effect for any one of the outcomes tested, it was considered positive. As previously stated, there appears to be a bias towards positive findings in the studies reported, particularly with the animal and human laboratory studies. Interestingly, there have been more clinical trials, compared with human laboratory studies, conducted on all drugs included in Fig. 1 and Supporting Information Table 1 . This suggests that there is less information being obtained concerning mechanism of action and dosing and more of an emphasis on efficacy outcomes. The mechanism of action can provide insight that can be advantageous when designing a clinical trial such as by helping to determine the patient population most likely to respond to the drug, identifying the most suitable drinking endpoint, establishing a more accurate dosing regimen, or predicting common side effects associated with the drug (Editorial, 2010) . The central questions remaining are: what specific animal paradigms are predictive of human laboratory and clinical trial success and which human laboratory paradigms are predictive of clinical trial success. Further, it remains crucial to identify which experimental paradigms (in animal and in humans) can meaningfully inform our understanding of mechanisms of action of AUD pharmacotherapies and can in turn help target medications to patient populations on the basis of these mechanisms.
CONCLUSIONS
While only four pharmacotherapies are currently approved for the indication of AUD and their efficacy is small-to-moderate, the past two decades has seen extensive research on medications development for AUD. The neuropharmacology of alcohol is such that it targets multiple brain systems, thus offering unique challenges and opportunities. Research to date has focused primarily on medications targeting endogenous opioids and associated DA release in the ventral striatum, a brain region often implicated in the rewarding properties of alcohol and drugs. More recently, however, increased attention has been paid to novel targets, such as corticotropinreleasing factor, P2X4Rs, and the neuroimmune system. Medications in these novel drug classes are still early in their development, and their potential efficacy remains unclear. The primary goal of this paper was to provide a perspective on medications development for AUD along with an illustrative review of the literature encompassing preclinical, human laboratory, and clinical trials. In order to provide an up-to-date survey of the field, medications undergoing testing were identified from clinicaltrials.gov, and extensive literature searches were conducted. Tables were developed to characterize the medications and their purported mechanisms of action (Table 1) , preclinical studies including animal models selected and results obtained (Table 2) , human laboratory studies including experimental paradigms, population studied, and results (Table 3) , and clinical trials, including abstinence period at study entry, treatment and dosing protocol, and results from primary outcomes (Table 4) . Finally, a comparison across animal, human laboratory, and clinical trial findings was provided for pharmacotherapies for which three or more clinical trials were completed to date ( Fig. 1 ; Supporting Information Table 1 ).
This extensive effort towards covering a large body of research has allowed us to derive some important Figure 1 Translational research outcomes figure with depicting the number of positive (right side) and negative (left side) outcomes for each clinical trial (white bars), human laboratory study (gray bar) and animal study (black bar). Note: Only pharmacotherapies with three or more reported clinical trials were included conclusions and recommendations for the field. While a critical interpretation of the studies summarized in the tables is provided at each level of analysis (i.e., preclinical, human lab, and clinical trials), some general conclusions can also be drawn. Specifically, there is a marked need for standardization of testing procedures at each level of medications development, including standard protocols for experimental paradigms, population characteristics (in both animal and human studies), and analyses of predefined primary and secondary outcomes. Such standardization would allow us to more effectively integrate results from various studies using both critical reviews of the literature as well as quantitative studies (i.e., meta-analysis). In addition, opportunities for studies that can more effectively detect ideal dosing and mechanisms of action were highlighted throughout the review. Finally, it is important to recognize that this review ends at the efficacy testing stage, namely, clinical trials. The dissemination of these findings at the level of effectiveness studies and public health efforts represents an important next frontier from the development of efficacious medications. In the current healthcare context, only a very small minority of patients ever receive a medication for the treatment of AUD (Bates, 2005) and dissemination of research findings to the clinical community represents a crucial step towards the ultimate goal of alleviating suffering from this prevalent and debilitating disorder.
